| Central Montana Hearing & Audiology, P.c. | |
|
625 Ne Main St, Suite 1, Lewistown, MT 59457-2084 | |
| (406) 538-5072 | |
| (406) 538-5059 |
| Full Name | Central Montana Hearing & Audiology, P.c. |
|---|---|
| Type | Facility |
| Speciality | Clinic/center - Hearing And Speech |
| Location | 625 Ne Main St, Lewistown, Montana |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447491287 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | (* (Not Available)) | Secondary |
| 261QH0700X | Clinic/center - Hearing And Speech | AU1068 (Montana) | Primary |
| Provider Name | Tina M Berg |
|---|---|
| Provider Type | Practitioner - Qualified Audiologist |
| Provider Identifiers | NPI Number: 1407906381 PECOS PAC ID: 7012982077 Enrollment ID: I20040901000851 |
News Archive
CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for self-administration of Berinert, C1 Esterase Inhibitor (Human), a pasteurized, nanofiltered therapy indicated for the treatment of acute attacks of hereditary angioedema (HAE), a rare and potentially fatal genetic disorder.
Watson Pharmaceuticals, Inc. today announced that its subsidiary Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Next Choice ONE DOSE (Levonorgestrel Tablet, 1.5 mg), the generic equivalent to Teva Women's Health's Plan B One-Step. Watson plans to launch the product immediately.
Regular blood tests before and during chemotherapy for prostate cancer can detect whether or not a patient is resistant or developing resistance to treatment with docetaxel, according to research presented at the NCRI Festival.
Four years ago, when meningitis B, an extremely rare but potentially lethal form of the infection, sickened a small number of college students at Princeton and the University of California-Santa Barbara, there was no vaccine against the disease sold in the U.S. Despite its availability abroad, it had never been licensed in the country due to its limited marketability.
British researchers from Bristol University say following a regular exercise programme can significantly reduce the risk of Alzheimer's disease by as much as a third.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Central Montana Hearing & Audiology, P.c. 625 Ne Main St, Suite 1, Lewistown, MT 59457-2084 Ph: () - | Central Montana Hearing & Audiology, P.c. 625 Ne Main St, Suite 1, Lewistown, MT 59457-2084 Ph: (406) 538-5072 |
News Archive
CSL Behring today announced that the U.S. Food and Drug Administration (FDA) has approved a label expansion for self-administration of Berinert, C1 Esterase Inhibitor (Human), a pasteurized, nanofiltered therapy indicated for the treatment of acute attacks of hereditary angioedema (HAE), a rare and potentially fatal genetic disorder.
Watson Pharmaceuticals, Inc. today announced that its subsidiary Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Next Choice ONE DOSE (Levonorgestrel Tablet, 1.5 mg), the generic equivalent to Teva Women's Health's Plan B One-Step. Watson plans to launch the product immediately.
Regular blood tests before and during chemotherapy for prostate cancer can detect whether or not a patient is resistant or developing resistance to treatment with docetaxel, according to research presented at the NCRI Festival.
Four years ago, when meningitis B, an extremely rare but potentially lethal form of the infection, sickened a small number of college students at Princeton and the University of California-Santa Barbara, there was no vaccine against the disease sold in the U.S. Despite its availability abroad, it had never been licensed in the country due to its limited marketability.
British researchers from Bristol University say following a regular exercise programme can significantly reduce the risk of Alzheimer's disease by as much as a third.
› Verified 9 days ago